The our proprietary Recycling Antibody® technology, in contrast to conventional antibodies which can only bind to the antigen once, enables a single antibody molecule to bind to an antigen multiple times. This is achieved by engineering the antibody to dissociate from the antigen at acidic pH within the endosome. Recycling Antibody® technology has been applied to create FDA-approved product, ENSPRYNG® (satralizumab), and we have multiple recycling antibodies that are now being tested in clinical study and in the drug discovery stage.
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Nature Biotechnology volume 28, pages 1203–1207 (2010)
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases
Scientific Reports volume 7, Article number: 1080 (2017)